Cardiac amyloidosis other imaging findings

Cardiac amyloidosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cardiac Amyloidosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cardiac amyloidosis other imaging findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cardiac amyloidosis other imaging findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiac amyloidosis other imaging findings
CDC onCardiac amyloidosis other imaging findings
Cardiac amyloidosis other imaging findings in the news
Blogs on Cardiac amyloidosis other imaging findings
Directions to Hospitals Treating Cardiac amyloidosis
Risk calculators and risk factors for Cardiac amyloidosis other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2] Raviteja Guddeti, M.B.B.S. [3] Aarti Narayan, M.B.B.S [4]

Overview

The initial imaging modality used in patients with suspected cardiac amyloidosis is echocardiography. The diagnosis of ATTR cardiac amyloid can then be confirmed with a nuclear scan (99mTc-PYP imaging), which can then guide the management.

Other Imaging Findings

Nuclear Cardiac Scanning

• 99mTechnetium-pyrophopshate (99mTc-PYP) is a widely available radiotracer.
• In conjunction with a cardiac or chest SPECT, 99mTc-PYP is infused and then the images are examined for visual interpretation and quantification of the degree of myocardial uptake.
• Qualitatively, myocardial uptake patterns are either absent, focal, diffuse, or focal on diffuse.
• A diffuse pattern is suggestive of ATTR cardiac amyloid.
• Quantitatively, radiotracer uptake in the the region of interest (ROI) in the heart (H) is compared to the uptake in the contralateral lung (CL) at 1 hour after tracer injection, which yields an H/CL ratio.
• A H/CL ratio of ≥ 1.5 is suggestive of ATTR cardiac amyloid.
• Alternatively, uptake in the ROI can be visually compared to the rib at 3 hours after tracer injection, with a visual score grade of > 2 (indicating uptake equal to that of the rib) suggestive of ATTR cardiac amyloid.

Targeted imaging

• Direct detection of amyloid fibrils is possible using molecular imaging using amyloid-binding PET tracers, such as:
  • 11-Pittsburgh compound-B
  • F-18-florbetapir
  • F-18-florbetaben
• Using these PET tracers enables to:
  • Measure global and regional amyloid burden deposited in the myocardium
  • Detect molecular changes in the fibril composition
• Tracer uptake can be assessed visually or using a number of indexes such as: target to-background ratio, myocardial retention index, and myocardial standardized uptake value.
• These tracers might provide the opportunity to evaluate cardiac and systemic amyloid deposits throughout the whole body (for example in AL amyloidosis)

References

Template:WikiDoc Sources CME Category::Cardiology